Summary: The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated. Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline. CYP1A2 and CYP3A4 also contributed to the metabolism of selegiline but their catalytic activities were much less than that of CYP2B6. CYP2B6 had a higher a‹nity for both N-depropagylation ( K m ＝21.4 mM) and Ndemethylation ( K m ＝25.2 mM) of selegiline than CYP3A4 and CYP1A2. In immunoinhibition studies using mixed human hepatic microsomes, selegiline N-depropagylation activity was most strongly inhibited by anti-CYP2B and anti-CYP3A antibodies, while selegiline N-demethylation activity was most inhibited by anti-CYP2B antibody. In CYP2B6-rich human hepatic microsomes, anti-CYP2B antibody had the strongest inhibitory eŠects on both activities. Selegiline inhibited CYP2B6-mediated (S)-mephenytoin Ndemethylation activity and CYP2C19-mediated (S)-mephenytoin 4?-hydroxylation activity. Theseˆnd-ings suggest that attention should be paid to the drug-drug interaction associated with CYP2B6 and CYP2C19.
Introduction

Selegiline hydrochloride [(")-(R)-N,a-dimethyl-N-2-
propynylphenethylamine hydrochloride] is a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B). 1) Selegiline is used both alone and together with levodopa for the treatment of Parkinson's disease. 2, 3) Selegiline is metabolized to N-desmethylselegiline and l-methamphetamine followed by l-amphetamine (Fig. 1) . CYPs (cytochrome P450 isoforms) participate in this metabolism of selegiline in rats. 4, 5) In humans, CYP2D6 and CYP3A4 have been reported to be involved with the metabolism of selegiline. 6, 7) However, Scheinin showed that CYP2D6 did not contribute to this metabolism: in that study, pharmacokinetic parameters of selegiline such as Cmax, tmax, t1W 2 and AUC did not diŠer signiˆcantly between poor and extensive metabolizers of debrisoquine.
8) The contribution of CYP1A2 and CYP3A4 to the formation of N-desmethylselegiline and participation of CYP3A4 to the formation of l-methamphetamine have been reported. 9, 10) The most recently, CYP2B6 and CYP2C19 have been reported to be the major enzymes responsible for the metabolism of selegiline. 11) It is not clear which CYP isoforms actually contribute, to what extent, to the metabolism of selegiline in humans.
In this study, we investigated the participation of CYP isoforms in the metabolism of selegiline using human hepatic microsomes and recombinant CYP isoforms expressed in human lymphoblastoid cells. The possibility of drug-drug interactions attributed to the inhibition of CYP-mediated metabolism by selegiline was also examined.
Materials and Methods
Materials: Selegiline hydrochloride [(")-(R)-N,adimethyl-N-2-propynylphenethylamine hydrochloride] was obtained from the Chinoin Pharmaceutical and Chemical Works Company (Budapest, Hungary). NDesmethylselegiline hydrochloride and l-amphetamine hydrochloride were synthesized by Fujimoto Pharmaceutical Co. Ltd (Osaka, Japan). l-Methamphetamine hydrochloride was purchased from Dainippon Pharmaceutical Co. Ltd (Osaka, Japan). The human hepatic microsomes designated HHM-195, HHM-223 and HHM-224 were obtained from the International Institute for the Advancement of Medicine (NJ, USA) while those designated as Ms-28 and Ms-17 were prepared from human livers obtained from the Karolinska Institute (Sweden). The preparation of these hepatic microsomes was performed as described elsewhere. 12) Pooled human hepatic microsomes and microsomes of human lymphoblastoid cells expressing CYP isoforms (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9 (Arg), CYP2C19, CYP2D6 (Val), CYP2E1, CYP3A4 and CYP4A11) were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan). Antibodies against rat CYP isoforms (CYP1A, CYP2A, CYP2B, CYP2C, CYP2D, CYP2E and CYP3A) were raised in female Japanese White rabbits obtained from Biotech (Saga, Japan) as described previously. 13) The following compounds were used as either substrates, metabolites or inhibitors: (S)-mephenytoin, (S)-nirvanol, 4-hydroxytolbutamide, 4?-hydroxymephenytoin, 1?-hydroxybufuralol, 6-hydroxychlorzoxazone, testosterone, 6b-hydroxytestosterone and ketoconazole from Daiichi Pure Chemicals Co., Ltd (Tokyo, Japan), methoxyphenamine hydrochloride, methoxsalen, 7-ethoxyresoruˆn, diethyldithiocarbamate, a-naphto‰a-vone, 7-hydroxycoumarin, orphenadrine, coumarin, tolbutamide, sulfaphenazole, quinidine, chlorzoxazone and tranylcypromine from SIGMA Chemical Co. (St. Louis, MO), and resoruˆn from Aldrich Chemical Co. (Milwaukee, WI). Glucose-6-phosphate, glucose-6-phosphate dehydrogenase, NADP (nicotinamideadenine dinucleotide phosphate) and NADPH were purchased from Oriental Yeast Co. (Tokyo, Japan). All other chemicals and organic solvents were obtained from Nacalai Tesque Co. (Kyoto, Japan).
Metabolism of selegiline by recombinant CYP isoforms: An incubation mixture containing microsomes (5.4 to 42 mL) of human lymphoblastoid cells (10 pmol of each CYP isoform) and 5 mL of 5 mM selegiline (ˆnal concentration, 100 mM) was adjusted to aˆnal volume of 230 mL by addition of 100 mM potassium phosphate buŠer (pH 7.4). The reaction was started by adding 20 mL of 10 mM NADPH. The mixture was incubated with gentle shaking for 15 min at 379 C. The reaction was terminated by adding 5 mL of 60z perchloric acid and then 5 mL of 100 mM methoxyphenamine solution was added to the mixture as an internal standard. The mixture was centrifuged at 12,000×  for 4 min and the supernatant was analyzed by HPLC-UV as follows to determine the amount of selegiline and its metabolites. A 50-mL aliquot of the supernatant was applied to a reversed phase column (TSKgel ODS-80Ts, 4.6×250 mm, TOSOH, Tokyo, Japan) using an autosampler (AS-8000, TOSOH, Tokyo, Japan). The column temperature was maintained at 459 C. The mobile phase consisting of 4 mM perchloric acid and acetonitrile (85:15) was delivered at a ‰ow rate of 1.0 ml W min. The detection was carried out using a UV detector (SPD-6AV, Shimadzu, Kyoto, Japan) at a wavelength of 215 nm. In the kinetic experiments, several concentrations of selegiline ranging from 25 to 700 mM were used to determine the kinetic parameters.
Inhibition study with anti-CYP antibodies: Inhibition studies using anti-CYP antibodies and human hepatic microsomes were carried out as follows. An incubation mixture containing 100 mg of microsomal protein and each anti-CYP antibody (50, 100 and 200 mg of IgG) was adjusted to aˆnal volume of 225 mL by addition of 100 mM potassium phosphate buŠer (pH 7.4). After the preincubation for 20 min at room temperature, 20 mL of 10 mM NADPH was added and the reaction was started by adding 5 mL of 5 mM selegiline (ˆnal concentration, 100 mM). The conditions for both the reaction and HPLC were as described above.
CYP isoform-speciˆc enzyme assays: Pooled human hepatic microsomes prepared from ten human livers were used in the assays. The following CYP isoform-speciˆc enzyme assays were employed; 7-ethoxyresoruˆn O-deethylation (CYP1A1 W 2), coumarin 7-hydroxylation (CYP2A6), 14) (S)-mephenytoin N-deethylation (CYP2B6), 15) tolbutamide 4-hydroxylation (CYP2C9), 16) (S)-mephenytoin 4?-hydroxylation (CYP2C19), 15) bufuralol 1?-hydroxylation (CYP2D6), 17) chlorzoxazone 6-hydroxylation (CYP2E1) 18) and testosterone 6b-hydroxylation (CYP3A4).
13) The reference inhibitors used in each assay were a-naphtho‰a-vone (CYP1A W 2), 19) methoxsalen (CYP2A6), 20) orphenadrine (CYP2B6), 21, 22) sulfaphenazole (CYP2C9), 23, 24) tranylcypromine (CYP2C19), 25) quinidine (CYP2D6), 24) diethyldithiocarbamate (CYP2E1) 24) and ketoconazole (CYP3A4). 23, 24) . Theˆnal concentration of selegiline and each reference inhibitor in the reaction mixture was 5, 20 and 100 mM except for ketoconazole (1 and 5 mM). The reaction was initiated by the addition of NADPH generating system (1.3 mM glucose-6-phosphate, 0.4 units of glucose-6-phosphate dehydrogenase, 3.3 mM MgCl 2 and 3.3 mM NADP). The metabolite produced in each reaction was identiˆed by HPLC.
Other methods: The enzyme kinetic parameters (Km and Vmax) were determined according to a nonlinear least squares regression analysis. The amount of CYP protein in human hepatic microsomes (HHM-195, HHM-223, HHM-224, Ms-17 and Ms-28) was measured by Western blot analysis.
26)
Results
Metabolism of selegiline by recombinant CYP isoforms: The metabolites of selegiline, methamphetamine and desmethylselegiline, were identiˆed by comparing their retention times on HPLC with those of the authentic compounds. l-Methamphetamine, N-desmethylselegiline and methoxyphenamine (internal standard) were eluted at 14.0, 21.3 and 23.2 min, respectively (Fig. 2) . Selegiline at aˆnal concentration of 100 mM was incubated in the microsomes of human lymphoblastoid cells expressing CYP isoforms and the catalytic activities for N-depropagylation and N-demethylation were measured (Fig. 3) . Among 11 recombinant CYP isoforms examined, CYP2B6 showed the highest level of activity for both N-depropagylation (5.70 pmol W min W pmol P450) and N-desmethylation (5.36 pmol W min W pmol P450). The catalytic activities of other recombinant CYP isoforms were less than 40z of those of CYP2B6. A contribution by CYP1A2 and CYP3A4 to the metabolism of selegiline was also observed, though to a lesser extent. Although CYP1A1 showed similar catalytic activity to CYP1A2 and CYP3A4, its contribution to the metabolism was considered to be minor because of its markedly low expression level in human liver.
27) The kinetic analysis was further carried out for CYP2B6, CYP1A2 and CYP3A4, and their kinetic parameters for the N-depropagylation and Ndemethylation of selegiline are listed in Table 1 . The Km values for the N-depropagylation and N-demethylation by CYP2B6 were 21.4 and 25.2 mM, respectively, much smaller than those of CYP1A2 and CYP3A4. The Vmax values for both the reactions diŠered little among the three CYP isoforms. Consequently, Vmax W Km values for both the N-depropagylation and N-demethylation of selegiline by CYP2B6 were much larger than those by CYP1A2 and CYP3A4.
Inhibition study with anti-CYP antibody: The inhibitory eŠect of anti-CYP antibody on the N- depropagylation and N-demethylation of selegiline in human hepatic microsomes (a mixture of HHM-195, HHM-223 and HHM-224) was investigated. Anti-CYP2B and anti-CYP3A antibodies inhibited the Ndepropagylation more potently than the other antibodies (Fig. 4) , while anti-CYP2B antibodies had the strongest eŠect on N-demethylation.
To examine the inhibitory eŠect of anti-CYP antibody on the two catalytic activities in human hepatic microsomes rich in CYP2B6 or in CYP1A2, Ms-28 and Ms-17 were used (Fig. 5) . The amount of CYP protein in these microsomes is shown in Table 2 . In Ms-28 rich in CYP2B6, anti-CYP2B antibody had the strongest inhibitory eŠect on both the N-depropagylation and Ndemethylation of selegiline of all the anti-CYP antibodies examined (Figs. 5A and 5B), with 56.9z and 67.0z inhibition, respectively, at 20 mL of antibody. In Ms-17 rich in CYP1A and poor in CYP2B6, anti-CYP1A antibody inhibited the two catalytic activities most potently than the other antibodies examined (Figs. 5C and 5D ). Anti-CYP2B antibody showed little inhibition of either activity in Ms-17.
Inhibitory eŠect of selegiline on the catalytic activity of CYP isoforms: The in‰uences of selegiline (5, 20 and 100 mM) on 7-ethoxyresoruˆn O-deethylation (CYP1A1 W 2), coumarin 7-hydroxylation (CYP2A6), (S)-mephenytoin N-demethylation (CYP2B6), tolbutamide 4-hydroxylation (CYP2C9), (S)-mephenytoin 4?-hydroxylation (CYP2C19), bufuralol 1?-hydroxylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1) and testosterone 6b-hydroxylation (CYP3A4) in pooled human hepatic microsomes were examined (Fig. 6 ). An inhibitory eŠect was observed on (S)-mephenytoin N-demethylation dependent on the concentration of selegiline, with 25.0z, 51.5z and 72.8z inhibition at 5, 20 and 100 mM of selegiline, respectively. The activity of (S)-mephenytoin 4?-hydroxylation was also inhibited 67.3z only at the highest concentration of selegiline (100 mM). The other CYP-mediated reactions were inhibited less than 32.0z. The reference inhibitors used as positive controls inhibited the activities of the respective CYPmediated reactions in a concentration-dependent manner; from 50z to 80z at 20 and 100 mM (data not shown).
Discussion
Several CYP isoforms such as CYP1A2, CYP2B6, CYP2C19, CYP2D6 and CYP3A4 have been known to contribute to the metabolism of selegiline, [7] [8] [9] [10] [11] but it is not clear which isoforms are most involved in the metabolism in humans. In this study, we investigated the contribution of CYP isoforms to the N-depropagylation and N-demethylation of selegiline using recombinant CYP isoforms and human hepatic microsomes.
Among the recombinant CYP isoforms expressed in human lymphoblastoid cells, CYP2B6 contributed markedly to both the N-depropagylation and N-demethylation compared with other CYP isoforms including CYP1A2, CYP2C19, CYP2D6 and CYP3A4. In the kinetic analysis, CYP2B6 displayed a much smaller Km value and much larger Vmax W Km value for both Ndepropagylation and N-demethylation than either CYP1A1 or CYP3A4. These results suggest that CYP2B6 is a high-a‹nity CYP isoform for the metabolism of selegiline in humans.
The participation of CYP2B6 in the metabolism of selegiline was conˆrmed by the following; anti-CYP2B antibody (100 mg IgG) inhibited both the N-depropagylation activity and N-demethylation activity of selegiline more than any other anti-CYP antibody in the mixed human hepatic microsomes. In addition, its inhibitory eŠect on both catalytic activities was strengthened in the CYP2B6-rich microsomes. These results indicate a major role for CYP2B6 in the metabolism of selegiline. However, anti-CYP1A antibody strongly inhibited both N-depropagylation and N-demethylation activities in the CYP1A2-rich and CYP2B6-poor human hepatic microsomes. Consequently, CYP2B6 is not the main isoform involved in the metabolism of selegiline in individuals with very low levels of CYP2B6 in liver. These immunoinhibition studies indicate that CYP2B6 is most involved in the metabolism of selegiline, but the degree of its contribution varies with the level of its expression in the liver.
The fact that selegiline inhibited CYP2B6-mediated (S)-mephenytoin-N-demethylation and CYP2C19-mediated (S)-mephenytoin 4?-hydroxylation activities suggests that attention should be paid to the drug-drug interactions associated with CYP2B6 and CYP2C19. The most recently, Hidestrand et al. reported that CYP2B6 and CP2C19 are the major enzymes responsible for the metabolism of selegiline. 11) There is the diŠerence in the contribution of CYP2C19 to the metabolism of selegiline between this recent report and our results, but the reason for this diŠerence is presently unknown.
In conclusion, CYP2B6 is closely involved in both the N-depropagylation and N-demethylation of selegiline, while CYP3A4 and CYP1A2 contribute to a lesser extent. However, the degree to which CYP2B6 contributes to the metabolism of selegiline in humans varies with the level of its expression in the liver. Consequently, contribution by CYP3A4 and CYP1A2 to the metabolism of selegiline is possible in case that the expression level of CYP2B6 is low.
